FDA AdComm Prep For Gilead’s Sofosbuvir Shows Agency Thinking On HCV Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA staff cites a favorable benefit-risk assessment for sofosbuvir, though evidence is insufficient to support dosing recommendation in patients with HCV genotypes 5 and 6. Dosing duration and use in prior nonresponders and pre-transplant patients will be discussed by Antiviral Drugs Advisory Committee Oct. 25.
You may also be interested in...
Janssen’s Simeprevir May Require Hep C Subpopulation Screening
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.